Leerink analyst David Larsen says the recent weakness in pharmacy benefit managers and the drug distribution group is "overdone," as he believes Mylan (MYL) has been taking the vast majority of the pricing increases that have occurred with EpiPen, not the pharmacy benefit managers and distributors. Further, the analyst estimates that Cardinal Health (CAH) has a "fee-for-service" deal with EpiPen, which means that there may be no benefit to the company for any price increase that occurs, and notes that Express Scripts (ESRX) gives back 80%-90% of EpiPen rebates to their plan customers. Larsen would be a buyer of CVS Health (CVS) on weakness.

Shares of health care facilities and managed care are in the spotlight on Monday after Florida announced late on Friday five winners of six-year Medicaid managed care contracts. Among the winners... To see the rest of the story go to thefly.com. See Story Here